Abstract

Choroideremia (CHM) is a X-linked recessive chorioretinal dystrophy due to deficiency of the CHM gene product, i.e., Rab escort protein isoform 1 (REP1). To date, gene therapy for CHM has shown variable effectiveness, likely because the underlying pathogenic mechanisms as well as genotype-phenotype correlation are not yet fully known. Small nucleotide variants leading to premature termination codons (PTCs) are a major cause of CHM, but about 20% of patients has CHM gene deletions. To improve understanding of the disease mechanisms, we analyzed molecular features of seven deletions involving the CHM gene sequence. We mapped the deletion breakpoints by using polymerase chain reaction, sequencing and array comparative genomic hybridization; to identify rearrangement-promoting DNA sequences, we analyzed genomic architecture surrounding the breakpoint regions. Moreover, in some CHM patients with different mutation types, we measured transcript level of CHM and of CHML, encoding the REP2 isoform. Scattered along the whole CHM gene and in close proximity to the deletion breakpoints we found numerous repeat elements that generate a locus-specific rearrangement hot spot. Unexpectedly, patients with non-PTC variants had increased expression of the aberrant CHM mRNA; CHML expression was higher than normal in a patient lacking CHM and its putative regulatory sequences. This latest evidence suggests that mechanisms regulating CHM and CHML gene expression are worthy of further study, because their full knowledge could be also useful for developing effective therapies for this hitherto untreatable inherited retinal degeneration.

Highlights

  • Choroideremia (CHM; MIM #303100) is an X-linked recessive condition characterized by slow progressive degeneration of choroid, photoreceptors and retinal pigmented epithelium

  • Small nucleotide variants leading to premature termination codons (PTCs) are a major cause of CHM, but about 20% of patients has CHM gene deletions

  • Patients with non-PTC variants had increased expression of the aberrant CHM mRNA; CHML expression was higher than normal in a patient lacking CHM and its putative regulatory sequences. This latest evidence suggests that mechanisms regulating CHM and CHML gene expression are worthy of further study, because their full knowledge could be useful for developing effective therapies for this hitherto untreatable inherited retinal degeneration

Read more

Summary

Introduction

Choroideremia (CHM; MIM #303100) is an X-linked recessive condition characterized by slow progressive degeneration of choroid, photoreceptors and retinal pigmented epithelium. Very relevant for clinical diagnosis is the evidence that carrier females may exhibit a wide spectrum of disease severity They are mainly asymptomatic or mildly symptomatic, with funduscopic examination often showing patchy areas of chorioretinal atrophy, a minority of cases presents a severe phenotype, with retinal and choroidal atrophy similar to that observed in affected males [2,3]. CHM is caused by sequence alteration of the CHM gene (HGNC:1940; MIM * 300390), which spans a genomic region of about 190 kb on chromosome Xq 21.2 and contains 15 exons [4] This gene encodes the ubiquitously expressed Rab Escort Protein 1 (REP1) that, to the closely related isoform REP2 (MIM * 118825), is an essential component of the Rab geranyl-geranyl transferase II complex [5,6], which catalyzes prenylation of ras-related Rab GTPases, a group of proteins with key role in of intracellular membrane trafficking regulation [7,8]. Derangement of vesicular trafficking, exocytosis and secretion have been observed in CHM fibroblasts and monocytes, in addition to crystals in peripheral blood lymphocytes and significant abnormalities in plasma fatty acid and red blood cell membrane [9,10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call